A pharmaceutical composition for treating cancer-related fatigue

By leveraging the synergistic effect of the drug combination of isobutyllast and dexamethasone, the problem of the inability to simultaneously control cancer tumor growth and alleviate cancer-related fatigue in existing technologies has been solved, achieving the dual effects of tumor suppression and fatigue improvement while reducing side effects.

CN122398815APending Publication Date: 2026-07-17JINAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610428499.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-02
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

There is a lack of effective treatments in the current technology to simultaneously control cancer tumor growth and alleviate cancer-related fatigue. Dexamethasone alone has limited effect on improving cancer-related fatigue and has significant side effects.

Method used

A pharmaceutical composition comprising 89%–94% isotetrastone and 6%–11% dexamethasone, formulated as tablets, capsules or injections, is provided for synergistic inhibition of tumor growth and improvement of cancer-related fatigue.

Benefits of technology

It significantly improves behavioral indicators related to cancer-related fatigue and has a synergistic effect in inhibiting tumor growth and improving fatigue, while reducing side effects and demonstrating good biosafety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

本发明涉及一种治疗癌因性疲乏的药物组合物，该药物组合物由有效成分和医学上可接受的辅料组成，其特征在于所述有效成分由以下重量百分比的原料药制成：异丁司特89%～94%，地塞米松6%～11%。本发明所述的有效成分既能有效抑制肿瘤生长，又能显著改善癌因性疲乏相关的行为学指标，而且在抑制肿瘤生长和改善癌因性疲乏这两方面都具有协同增效作用。
Need to check novelty before this filing date? Find Prior Art